Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer

• DOI: 10.1038/s41598-017-01268-4
• Publication Date: 2017-05-05T14:29:41Z
• Authors: A. S. Noman; M. Uddin; A. A. Chowdhury; M. J. Nayeem; Z. Raihan; M. I. Rashid; A. K. Azad; M. L. Rahman; D. Barua; A. Sultana; A. Shirin; J. Ferdous; R. R. Parag; S. M. Rahman; M. R. Mahmud; C. S. Jerin; N. Jahan; A. Siddiqua; T. Ara; E. B. Sabur; S. S. Alam; S. Baidya; S. Akther; M. Z. Rahman; T. Banu; A. K. Murugan; S. Sabri; S. M. S. Islam; B. Karakas; A. Aboussekhra; H. Yeger; W. A. Farhat; S. S. Islam
• Keywords: 0303 health sciences; Interleukin-6; Science; Q; R; Bone Neoplasms; Breast Neoplasms; Prognosis; Article; 3. Good health; 03 medical and health sciences; ROC Curve; Case-Control Studies; Biomarkers, Tumor; Disease Progression; Medicine; Humans; Female; Hedgehog Proteins; Whole Body Imaging; Neoplasm Metastasis; Neoplasm Staging

Abstract Serum from one hundred and ten breast cancer patients thirty healthy female volunteers, were prospectively collected evaluated for serum levels of Shh IL-6 using human specific enzyme-linked immunoassays. All regularly monitored event free survival (EFS) overall (OS). Overall outcome analysis was based on levels. In with progressive metastatic BC, both concentrations elevated in 44% (29 65) 63% (41 patients, respectively, at a statistically significant level [Shh (p = 0.0001) 0.0001)] compared to the low volunteers. tended increase progression lymph node positivity. High associated poor EFS OS opposite negative or lower IL-6. The mainly observed BC who had significantly higher risk early recurrence bone metastasis, worse BC. Further studies are warranted validating these biomarkers as prognostic tools larger patient cohort longer follow-up study.